Clinical Trial Detail

NCT ID NCT02048722
Title Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Northwestern University
Indications

angiosarcoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.